| 3rd Mar 2020 2:18 pm |
RNS |
Form-20F Publication |
| 3rd Mar 2020 12:15 pm |
RNS |
Final Results and Clinical Update |
| 25th Feb 2020 7:00 am |
RNS |
Notice of Results |
| 10th Feb 2020 7:00 am |
RNS |
Phase II Savolitinib / Imfinzi® Combination Data |
| 6th Feb 2020 4:35 pm |
RNS |
Price Monitoring Extension |
| 6th Feb 2020 7:20 am |
RNS |
Issue of Equity |
| 4th Feb 2020 4:40 pm |
RNS |
Second Price Monitoring Extn |
| 4th Feb 2020 4:35 pm |
RNS |
Price Monitoring Extension |
| 31st Jan 2020 7:00 am |
RNS |
Notice of Results |
| 29th Jan 2020 7:25 am |
RNS |
Holding(s) in Company |
| 23rd Jan 2020 7:35 am |
RNS |
Pricing of US$110 Million Public Offering of ADSs |
| 22nd Jan 2020 7:00 am |
RNS |
Chi-Med Announces Proposed Offering of ADSs |
| 20th Jan 2020 10:40 am |
RNS |
Positive SANET-p Phase III Clinical Trial Results |
| 13th Jan 2020 7:00 am |
RNS |
Chi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial |
| 6th Jan 2020 7:04 am |
RNS |
Chi-Med to Present at JP Morgan Conference |
| 31st Dec 2019 7:00 am |
RNS |
Block Listing Six Monthly Return |
| 31st Dec 2019 7:00 am |
RNS |
Total Voting Rights |
| 20th Dec 2019 7:00 am |
RNS |
Surufatinib Granted Priority Review in China |
| 12th Dec 2019 8:57 am |
RNS |
Grant of share options |
| 29th Nov 2019 8:56 am |
RNS |
Total Voting Rights |
| 28th Nov 2019 7:00 am |
RNS |
Elunate® Included in China NRDL |
| 25th Nov 2019 7:47 am |
RNS |
Chi-Med Highlights Presentations at 2019 ESMO Asia |
| 25th Nov 2019 7:00 am |
RNS |
Surufatinib granted FDA orphan drug designation |
| 11th Nov 2019 7:00 am |
RNS |
Surufatinib China NDA acceptance |
| 17th Oct 2019 7:26 am |
RNS |
Chi-Med Ph II gastric cancer data for Savolitinib |
| 10th Oct 2019 10:22 am |
RNS |
Grant of share options under share option scheme |
| 10th Oct 2019 9:00 am |
RNS |
Innovent and Chi-Med Expand Global Collaboration |
| 4th Oct 2019 7:11 am |
RNS |
Chi-Med Phase I/Ib Trial of HMPL-523 in Lymphoma |
| 3rd Oct 2019 8:26 am |
RNS |
Holding(s) in Company |
| 30th Sep 2019 1:49 pm |
RNS |
Holding(s) in Company |
| 30th Sep 2019 12:11 pm |
RNS |
Holding(s) in Company |
| 30th Sep 2019 7:00 am |
RNS |
Chi-Med Surufatinib Phase III data at ESMO |
| 30th Sep 2019 7:00 am |
RNS |
Total Voting Rights |
| 25th Sep 2019 7:00 am |
RNS |
Chi-Med Presents SANET-ep Phase III data at ESMO |
| 18th Sep 2019 7:00 am |
RNS |
Chi-Med Highlights Presentations at 2019 CSCO |
| 3rd Sep 2019 7:19 am |
RNS |
Chi-Med to present at MS conference |
| 3rd Sep 2019 7:00 am |
RNS |
Chi-Med initiates Phase I trial |
| 30th Aug 2019 7:00 am |
RNS |
Total Voting Rights |
| 23rd Aug 2019 7:00 am |
RNS |
Start of Clinical Trial in China |
| 20th Aug 2019 7:48 am |
RNS |
Holding(s) in Company |
